Biochimica et biophysica acta. Reviews on cancer最新文献_第4页

Targeting palmitoylation: A novel frontier in cancer biology and immunotherapy 靶向棕榈酰化：癌症生物学和免疫治疗的新前沿。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-07 DOI: 10.1016/j.bbcan.2025.189509

Ye Yang , Enqi Zhang , Xuanli Mao , Guohong Liu , Yunbao Pan

{"title":"Targeting palmitoylation: A novel frontier in cancer biology and immunotherapy","authors":"Ye Yang , Enqi Zhang , Xuanli Mao , Guohong Liu , Yunbao Pan","doi":"10.1016/j.bbcan.2025.189509","DOIUrl":"10.1016/j.bbcan.2025.189509","url":null,"abstract":"<div><div>Protein palmitoylation, a dynamic post-translational modification involving the reversible attachment of palmitic acid to cysteine residues, has emerged as a pivotal regulator of tumor biology. This review synthesizes the latest insights into palmitoylation's contributions to cancer, emphasizing its roles in metabolic reprogramming, oncogenic signaling, immune modulation, and therapeutic responsiveness. The ZDHHC family of palmitoyltransferases, in concert with depalmitoylases, coordinates intricate regulatory networks that govern protein localization, stability, and interactions essential for tumor proliferation, invasion, and immune evasion. Driven by dysregulated lipid metabolism, aberrant palmitoylation modulates key pathways such as AKT-mTOR and Wnt/β-catenin, while also stabilizing immune checkpoints like PD-L1 and TIM-3 to sculpt an immunosuppressive tumor microenvironment. Advances in multi-omics integration and detection technologies, including high-resolution mass spectrometry and imaging modalities, have deepened our mechanistic understanding of these processes. Preclinical evidence underscores the promise of small-molecule inhibitors like 2-bromopalmitate and TVB-3166, which disrupt palmitoylation to inhibit tumor growth and potentiate immunotherapy. Nonetheless, hurdles in selectivity, toxicity, and resistance demand further optimization for clinical translation. Future research should focus on unraveling palmitoylation's interplay with immune dynamics and advancing biomarker-guided, personalized therapies to elevate cancer outcomes.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189509"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of microRNAs in the regulation of RKIP and signaling pathways in cancer microrna在肿瘤中调控RKIP和信号通路中的作用。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-09 DOI: 10.1016/j.bbcan.2025.189508

Graziana Spoto , Massimo Libra , Luca Falzone

{"title":"Role of microRNAs in the regulation of RKIP and signaling pathways in cancer","authors":"Graziana Spoto , Massimo Libra , Luca Falzone","doi":"10.1016/j.bbcan.2025.189508","DOIUrl":"10.1016/j.bbcan.2025.189508","url":null,"abstract":"<div><div>Raf kinase inhibitor protein (RKIP), also known as Phosphatidyl Ethanolamine Binding Protein (PEBP1), is a pivotal modulator of multiple intracellular signaling cascades involved in tumorigenesis, progression, metastasis, and cancer therapy resistance. In recent years, increasing evidence has highlighted the regulatory role of non-coding RNAs, particularly microRNAs (miRNAs), in modulating RKIP expression and activity across various types of cancer. This review aims to comprehensively summarize current knowledge on the post-transcriptional regulation of RKIP by miRNAs, elucidating their impact on tumor biology.</div><div>For this purpose, a systematic analysis of published experimental studies was conducted, focusing on both solid and hematological malignancies. The review discusses how miRNAs, such as miR-23a, miR-27a, miR-224, miR-181a, and others, directly or indirectly suppress RKIP, contributing to enhanced proliferation, invasion, epithelial-mesenchymal transition (EMT), cancer stem cell (CSC) traits, and radioresistance. Additionally, long non-coding RNAs (lncRNAs) like XIST and PEBP1P2 were identified as factors able to modulate RKIP suppression by acting as molecular sponges for miRNAs or stabilizing RKIP transcripts.</div><div>All the data presented in the manuscript are supported by diverse experimental approaches, including transcriptional analyses, functional in vitro assays (migration, invasion, apoptosis), gain- and loss-of-function experiments, luciferase reporter assays, and in vivo xenograft models, further validating the miRNA-RKIP axis involved in the progression of multiple tumors.</div><div>In conclusion, this review provides an integrated view of the complex post-transcriptional network governing RKIP regulation in cancer, underscoring the potential of targeting RKIP-associated non-coding RNA axes for innovative therapeutic strategies aimed at halting tumor progression and overcoming treatment resistance.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189508"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145746233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-29 DOI: 10.1016/j.bbcan.2025.189525

Jagannath Pradhan, Archana Priyadarshini Samal, Uzma Khatoon, Monica Prusty, Selvakumar Elangovan

{"title":"Estrogen-related receptor α in breast cancer: From molecular insights to targeted therapy","authors":"Jagannath Pradhan, Archana Priyadarshini Samal, Uzma Khatoon, Monica Prusty, Selvakumar Elangovan","doi":"10.1016/j.bbcan.2025.189525","DOIUrl":"10.1016/j.bbcan.2025.189525","url":null,"abstract":"<div><div>Breast cancer outcomes continue to be undermined by metastasis, relapse, and therapeutic resistance. While endocrine and targeted therapies have improved clinical outcomes, aggressive subtypes such as HER2-positive and triple-negative breast cancers remain challenging, exhibiting poor prognosis and frequent relapse. The constitutively active orphan nuclear receptor, estrogen-related receptor α (ERRα), has emerged as a key regulator of tumor energy metabolism and a crucial driver of breast cancer progression. The ERRα overexpression, frequently observed in aggressive subtypes, is strongly correlated with epithelial-mesenchymal transition, angiogenesis, invasion, metastasis, and therapy resistance. Preclinical studies demonstrate that pharmacological inhibition or gene silencing of ERRα suppresses oncogenic signaling and enhances therapeutic sensitivity. This review explores the multifaceted roles of ERRα in breast cancer and highlights its translational potential as a molecular target for treating aggressive breast cancer subtypes.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189525"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancement in preclinical development of cancer treatment agents through modulation of Rac1: From EHop-016 to natural products 通过调节Rac1的癌症治疗药物的临床前开发进展：从EHop-016到天然产物。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-24 DOI: 10.1016/j.bbcan.2025.189522

Yingyi Liu , Sze-Nga Wong , Aiping Lyu , Joshua Ka-Shun Ko

{"title":"Advancement in preclinical development of cancer treatment agents through modulation of Rac1: From EHop-016 to natural products","authors":"Yingyi Liu , Sze-Nga Wong , Aiping Lyu , Joshua Ka-Shun Ko","doi":"10.1016/j.bbcan.2025.189522","DOIUrl":"10.1016/j.bbcan.2025.189522","url":null,"abstract":"<div><div>Rac1 belongs to the Rac subfamily under the Rho family of GTPases. As an effector of K-Ras protein encoded by the <em>KRAS</em> gene, Rac1 activation plays a key role in KRAS-driven cancer development and is largely involved in the promotion of cell migration and chemoresistance in pancreatic cancer. Evidence has indicated that pancreas-specific knockdown of <em>Rac1</em> may prevent disease progression, while pharmacological inhibition of Rac1 can exert strong anti-cancer effects. In this review, we have discussed the relationship between Rac1 and neoplastic development, whereas different treatment schemes on pancreatic cancer through modulation of Rac1 during chemotherapy will be emphasized. Furthermore, we elaborated on contemporary studies of the Rac1 inhibitor EHop-016 and related compounds that have shown anti-tumor capability in preclinical models and their potential clinical applications. Exploration on the therapeutic prospect of phytochemicals derived from natural products capable of inhibiting cancer cell growth and disease progression by modulating Rac1 has been envisaged. Lastly, the complex correlation between Rac1 signaling and autophagy during treatment of pancreatic cancer by the novel phytochemical isoliquiritigenin would be introduced.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189522"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in breast cancer mRNA vaccines: Current development and future prospects 乳腺癌mRNA疫苗的进展：目前的发展和未来展望。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.bbcan.2025.189515

Wen Zheng , Wenjie Chen , Gyorgy Hutvagner , Laura Rangel-Sanchez , Wei Deng

{"title":"Advancements in breast cancer mRNA vaccines: Current development and future prospects","authors":"Wen Zheng , Wenjie Chen , Gyorgy Hutvagner , Laura Rangel-Sanchez , Wei Deng","doi":"10.1016/j.bbcan.2025.189515","DOIUrl":"10.1016/j.bbcan.2025.189515","url":null,"abstract":"<div><div>Messenger RNA (mRNA) vaccines have become a transformative approach in immunotherapy and have attracted significant attention owing to their unprecedented success in controlling COVID-19. With their ability to flexibly and specifically encode tumour-associated antigens, along with their favorable safety profiles and scalable manufacturing, mRNA vaccines represent a highly promising platform for cancer treatment. Breast cancer is a heterogeneous disease and many of its subtypes are immunologically cold tumours, which has limited the progress of immunotherapy in this field. Recent studies have highlighted the potential of mRNA vaccines to reshape the tumour immune microenvironment in breast cancer. These vaccines can enhance antigen presentation, activate T cell responses, and convert immunologically cold tumours into immune-active ones. This review provides a comprehensive overview of recent advances in mRNA vaccine development for breast cancer with a focus on antigen selection, mRNA design, and delivery strategies. It also examines findings from both preclinical and clinical studies as well as recent progress in industrial development. Finally, we discuss the current challenges hindering the clinical translation and ethical considerations of mRNA vaccine technology and propose future directions to advance mRNA vaccine-based therapies for breast cancer.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189515"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer 相同的突变，不同的命运：braf驱动的黑色素瘤和结直肠癌治疗反应的阴阳。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-02 DOI: 10.1016/j.bbcan.2025.189503

Carme Solé-Blanch , Sofia España , Alba de la Puente-Noel , Oskar Marin-Béjar , José Luis Manzano , Anna Martinez-Cardús

{"title":"Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer","authors":"Carme Solé-Blanch , Sofia España , Alba de la Puente-Noel , Oskar Marin-Béjar , José Luis Manzano , Anna Martinez-Cardús","doi":"10.1016/j.bbcan.2025.189503","DOIUrl":"10.1016/j.bbcan.2025.189503","url":null,"abstract":"<div><div>BRAF mutations are key oncogenic drivers across multiple cancers, yet their therapeutic exploitation varies markedly by tumor type. In melanoma, the combination of BRAF and MEK inhibitors has revolutionized treatment, yielding unprecedented clinical benefits. However, both intrinsic and acquired resistance mechanisms continue to limit long-term efficacy. In contrast, BRAF-targeted therapies in colorectal cancer (CRC) have shown limited success, even when combined with EGFR inhibitors to counteract compensatory survival pathways. Despite these differences, resistance ultimately emerges in both malignancies, driven by partially overlapping mechanisms that remain incompletely understood in CRC. This review dissects the “yin-yang” of BRAF as a therapeutic vulnerability in these two malignancies, we underscore the critical importance of tumor-specific context in precision oncology. Understanding the divergent responses to BRAF inhibition across cancer types is essential to refine current approaches and guide the development of more effective, personalized treatment strategies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189503"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Organoids as a new approach in advancing cancer therapies for hematologic malignancies 类器官作为推进血液恶性肿瘤肿瘤治疗的新途径。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-11 DOI: 10.1016/j.bbcan.2025.189514

Abdul Momin Muhammad Wisal , Raheleh Farahzadi , Gayathri Rajaraman , Ezzatollah Fathi

{"title":"Organoids as a new approach in advancing cancer therapies for hematologic malignancies","authors":"Abdul Momin Muhammad Wisal , Raheleh Farahzadi , Gayathri Rajaraman , Ezzatollah Fathi","doi":"10.1016/j.bbcan.2025.189514","DOIUrl":"10.1016/j.bbcan.2025.189514","url":null,"abstract":"<div><div>Cancer remains one of the leading causes of mortality worldwide. Among these, hematologic malignancies originating in the bone marrow present unique challenges for <em>in vivo</em> modeling due to their complex pathophysiology and dynamic microenvironment. Over the years, numerous approaches have been developed better to understand cancer initiation, progression, and therapeutic resistance. The advent of three-dimensional (3D) organoid culture has accelerated progress in molecular and cellular oncology by providing physiologically relevant models that recapitulate key aspects of human tissues. Derived from pluripotent stem cells or patient-derived samples, organoids replicate essential structural and functional features of native tissues, thereby enabling detailed investigations of disease progression, immune interactions, and treatment responses. This review outlines the historical development and emerging applications of organoid systems in cancer research. Furthermore, introduce hematologic organoids and how bone marrow (BM), lymph nodes (LNs), thymus, and spleen organoids can replicate the hematologic malignancies for personalized therapies and research studies. Additionally, we highlight the influences of key signaling pathways—including Notch, TGF-β, JAK/STAT, and Hedgehog—in regulating hematopoiesis and leukemogenesis within hematologic organoid platforms. Moreover, advances in co-culture systems that integrate tumor cells with stromal and immune components have provided powerful tools for modeling the hematology tumor microenvironment by enhancing preclinical drug testing and introducing personalized therapeutic strategies. As the field advances, the integration of organoid technology with bioengineering approaches and multi-omics platforms is expected to revolutionize translational research and accelerate the development of novel therapies for hematologic cancers.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189514"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular markers in oral squamous cell carcinoma: Insights into the tumor microenvironment, epigenetic regulation, and intercellular communications 口腔鳞状细胞癌的分子标记：肿瘤微环境、表观遗传调控和细胞间通讯的见解。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.bbcan.2025.189516

Xiaoran Zhen , Dongyan Zhang , Dongbao Li , Bo Fu , Keyi Li

引用次数: 0

The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies 4-1BB和基于cd28的CD19 CAR-T产品在b细胞恶性肿瘤治疗中的竞争

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1016/j.bbcan.2025.189519

Marta Krawczyk , Magdalena Drużyńska , Emilia Bednarska , Magdalena Winiarska

引用次数: 0

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-26 DOI: 10.1016/j.bbcan.2025.189523

Yashfeen Munib Siddiqui , Ilma Shakeel , Gulam Mustafa Hasan , Md. Imtaiyaz Hassan

{"title":"NIMA-related Kinase 2: A master regulator of mitotic fidelity and chromosomal instability in cancer: From mechanisms to therapeutic targeting","authors":"Yashfeen Munib Siddiqui , Ilma Shakeel , Gulam Mustafa Hasan , Md. Imtaiyaz Hassan","doi":"10.1016/j.bbcan.2025.189523","DOIUrl":"10.1016/j.bbcan.2025.189523","url":null,"abstract":"<div><div>NEK2 (NIMA-Related Kinase 2), a serine/threonine kinase, is a pivotal kinase for centrosome separation and mitotic fidelity. It is increasingly recognized as a driver of oncogenesis and a contributor to therapeutic resistance. This review comprehensively discusses the structural features, expression patterns, and multilayered regulation of NEK2, along with its interactions with signaling molecules, its function, and an in-depth investigation of its roles in various diseases, specifically different types of cancers. It further highlights NEK2's involvement in signaling pathways, its contribution to chromosomal instability and tumor progression, and its potential as both a biomarker and therapeutic target in cancer. Dysregulated NEK2 causes chromosomal instability, metastatic progression, and immune evasion across diverse cancers by disrupting centrosome dynamics, rewiring oncogenic pathways (e.g., PI3K-AKT, Wnt/β-catenin), and inactivating tumor suppressors such as p53. Overexpression of NEK2 correlates with poor prognosis and chemoresistance in haematological and solid tumors, suggesting its role as a biomarker and therapeutic target. Apart from its role in cancer, dysfunction of NEK2 contributes to polycystic kidney disease, bone remodeling, and immune dysregulation, highlighting its pleiotropic roles. Recent advances in targeting NEK2 include covalent inhibitors (e.g., JH295), Hec1 disruptors (e.g., INH154), and clinical-stage compounds (e.g., T-1101), alongside emerging strategies such as PROTACs and immunotherapy. However, challenges remain in developing selective, clinically viable agents. This review provides details on the molecular architecture of NEK2, disease mechanisms, and therapeutic potential, framing it as a dual regulator and guardian of mitosis that has become a rogue oncogene and advocating its exploitation in translational medicine across cancer and non-cancer pathologies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189523"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145851828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0